Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction
- Cindolo L.
- Natoli C.
- De Nunzio C.
- De Tursi M.
- Valeriani M.
- Giacinti S.
- Micali S.
- Rizzo M.
- Bianchi G.
- Martorana E.
- Scarcia M.
- Ludovico G. M.
- Bove P.
- Laudisi A.
- Selvaggio O.
- Carrieri G.
- Bada M.
- Castellan P.
- Topazio L.
- Boccasile S.
- Ditonno P.
- Chiodini P.
- Schips L.
Publication date
January 2017
DOIAbstract
Abiraterone acetate (AA) gives a significant improvement in survival for patients with metastatic castration-resistant prostate cancer (mCRPC) before and after chemotherapy and has a favorable effect on patients' health-related quality of life and pain. Only a few studies have investigated patient-reported outcomes (PROs) in AA treatment for mCRPC. The aim of this study was to investigate patients' satisfaction in men affected by mCRPC treated with AA
Add to ORKG